Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MiraLAX generic

This article was originally published in The Tan Sheet

Executive Summary

Perrigo expects to ship immediately its OTC laxative polyethylene glycol 3350, powder to solution, following FDA approval of an abbreviated new drug application. Positioned as an equivalent to Schering-Plough Healthcare Products' MiraLAX laxative, the OTC drug will be sold under store-brand labels, the company notes. Perrigo had said it would be market-ready when Schering's exclusivity for the laxative drug expired Oct. 6 (1"The Tan Sheet" July 13, 2009)

You may also be interested in...

Perrigo expects private-label MiraLAX launch in October

The firm prepares to be market-ready when Schering-Plough's exclusivity expires Oct. 6 for its OTC laxative MiraLAX. The expiry brings the "market formation date" and Perrigo expects "to be there," said Art Shannon, VP of investor relations and communications. Without exclusivity for the innovator, other firms can ask FDA to approve abbreviated new drug applications for equivalent products. Firms do not receive ANDA approval for the product until closer to Oct. 6, Shannon explained

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts